Basilea Pharmaceutica (OTCMKTS:BPMUF) Hits New 1-Year High – Should You Buy?

Basilea Pharmaceutica AG (OTCMKTS:BPMUFGet Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $52.83 and last traded at $52.83, with a volume of 0 shares traded. The stock had previously closed at $52.83.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised shares of Basilea Pharmaceutica to a “strong-buy” rating in a report on Monday, September 23rd.

Check Out Our Latest Research Report on Basilea Pharmaceutica

Basilea Pharmaceutica Price Performance

The business’s 50-day moving average is $51.95 and its two-hundred day moving average is $49.11.

Basilea Pharmaceutica Company Profile

(Get Free Report)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

Featured Articles

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.